Ruben Sebastian-Perez

Senior Associate

2024

• Board Director at cancer immunology newco: Led Seed round, company building, strategic and operational setup, deal sourcing and due diligence • Board Observer at Aboleris Pharma: Led Series A round, deal sourcing and due diligence Criteria Bio Ventures is a leading life sciences venture fund investing in transformative companies to shape the future of healthcare. CBV teams up with driven entrepreneurs and fellow investors to build innovative companies with the potential to transform patients’ lives. CBV invests in global biotech companies that provide disruptive therapeutic approaches centered on addressing unmet medical needs, with a primary focus on Europe. Criteria Bio Ventures is part of Caixa Capital Risc and the CriteriaCaixa group, Spanish largest investment holding with €28+ billion assets under management.

Associate

2023 - 2023

Investment Analyst

2021 - 2022

Board Director & Founding member

2023

Board Observer

2023

• Criteria Bio Ventures led the €30M Series A • Aboleris Pharma is a biotech company translating a fundamental discovery into novel pipeline-in-a-product immunotherapies designed to induce immune tolerance while preserving beneficial immune responses for autoimmune and inflammatory diseases such as rheumatoid arthritis

Senior Associate

2021

Senior Associate (2024+), previously Associate (2023) and Analyst (2021-2022). Founded in 2007, Caixa Capital Risc is a leading venture capital firm that invests in life sciences through its specialized fund Criteria Bio Ventures. Caixa Capital Risc is the VC firm of CriteriaCaixa, Spanish largest investment holding with €28+ Bn AUM.

Board Member

2023

• Board Member of YVC Collective and of the YVC Therapeutics chapter • Founder and Chair of the YVC Barcelona & Spain regional chapter

Advisor and Member of the International Expert Panel - CaixaImpulse Innovation

2022

Venture Advisor - Biopharma/Therapeutics

2020 - 2021

Evaluated life science companies seeking funding with MBX Capital. MBX Capital is a venture capital partnership focused on emerging companies pursuing critical challenges in public health. MBX invests in early-stage biopharma and healthtech companies based in US and Canada.

Technology & Business Development Fellow

2020 - 2021

Assisted the Technology & Business Development Office (TBDO) in translating innovative discoveries and technologies developed at CRG and CNAG (National Center for Genomic Analysis) into the commercial sector. • Advised entrepreneurs on R&D, intellectual property protection and commercialization strategies • Assessed the scientific, clinical and business value of the asset and entrepreneurial project, including technical feasibility and competitive landscape • Revised intellectual property documentation and collaborate with external international life science specialized IP law firms for patent filings • Engaged with key opinion leaders (KOLs) to gather feedback on the opportunity • Identified potential industry partners, business development alliances, investors or collaborators interested in developing the technology to the next stage • Defined and develop commercialization strategies • Prepared pitch decks and other internal documents for potential licensees, investors or collaborators

PhD Researcher

2017 - 2021

• Awarded FI-AGAUR fellowship for early-stage researchers, funded by Catalan Government and European Social Fund • Co-authored 7 peer-reviewed publications in multiple leading journals, including Molecular Cell, eLife and Nucleic Acids Research • Mentored undergraduate and master students, now working in academia and industry • Set up several international research collaborations with diverse teams in China (Guangzhou Institutes of Biomedicine and Health, GIBH and Beijing Genomics Institute, BGI) and Israel (Hebrew University of Jerusalem) • Participated in international collaborative projects with teams in the US (Harvard Medical School, University of Pennsylvania, Columbia University and Wyss Institute) and Spain (Institute for Bioengineering of Catalonia, IBEC; Barraquer Ophthalmology Center and Institute of Photonic Sciences, ICFO) • Led scientific projects, coordinated research partners and wrote project reports and manuscripts for publication • Presented scientific results in oral and poster format at multiple national and international conferences (Boston, US; Guangzhou, CN; Kyrenia, CY; Prague, CZ; Barcelona, ES) • Founded and chaired the Chromatin Club (monthly journal club) PhD Thesis: De novo heterochromatin establishment in 2C-like cells and early embryonic development. Reprogramming and Regeneration group | Gene Regulation, Stem Cells and Cancer Program

Research Scientist

2016 - 2017

Project: Development of single locus imaging technology for live and STORM microscopy exploiting the dCas9 system. Reprogramming and Regeneration group | Gene Regulation, Stem Cells and Cancer Program

Research Scientist

2015 - 2016

Project: Identification of glycosylated proteins in Mycoplasma species. Molecular Biology laboratory | Applied Proteomics and Protein Engineering Program

Teaching Assistant

2014 - 2015

Department of Biochemistry and Molecular Biology Department of Genetics and Microbiology